{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T13:46:50Z","timestamp":1770990410832,"version":"3.50.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,25]],"date-time":"2025-12-25T00:00:00Z","timestamp":1766620800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"vor","delay-in-days":50,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["824B2063"],"award-info":[{"award-number":["824B2063"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Innovation Fund for Outstanding Doctoral Candidates of Peking University Health Science Centre","award":["BMU2024BSS001"],"award-info":[{"award-number":["BMU2024BSS001"]}]},{"DOI":"10.13039\/501100005198","name":"Chinese Foundation for Hepatitis Prevention and Control","doi-asserted-by":"publisher","award":["GRG202301"],"award-info":[{"award-number":["GRG202301"]}],"id":[{"id":"10.13039\/501100005198","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-025-07455-6","type":"journal-article","created":{"date-parts":[[2025,12,25]],"date-time":"2025-12-25T06:03:34Z","timestamp":1766642614000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Serum N-glycomics for non-invasive detection of significant liver pathology across clinical phases of treatment-na\u00efve chronic hepatitis B"],"prefix":"10.1186","volume":"24","author":[{"given":"Xinjie","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meijie","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinbao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shanshan","family":"Ji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pengyuan","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuqi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cuiying","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoling","family":"Chi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1365-9862","authenticated-orcid":false,"given":"Tao","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,25]]},"reference":[{"key":"7455_CR1","unstructured":"WHO Guidelines Approved by the Guidelines Review Committee. In Guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection. Geneva: World Health Organization \u00a9 World Health Organization 2024.;2024."},{"key":"7455_CR2","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/S2468-1253(23)00197-8","volume":"8","author":"Global prevalence","year":"2023","unstructured":"Global prevalence. Cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study. Lancet Gastroenterol Hepatol. 2023;8:879\u2013907.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"7455_CR3","first-page":"1425","volume":"11","author":"H You","year":"2023","unstructured":"You H, Wang F, Li T, Xu X, Sun Y, Nan Y, Wang G, Hou J, Duan Z, Wei L, et al. Guidelines for the prevention and treatment of chronic hepatitis B (version 2022). J Clin Transl Hepatol. 2023;11:1425\u201342.","journal-title":"J Clin Transl Hepatol"},{"key":"7455_CR4","doi-asserted-by":"publisher","unstructured":"EASL Clinical Practice. Guidelines on the management of hepatitis B virus infection. J Hepatol. 2025;83(2):502\u201383. https:\/\/doi.org\/10.1016\/j.jhep.2025.03.018","DOI":"10.1016\/j.jhep.2025.03.018"},{"key":"7455_CR5","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/S2468-1253(24)00089-X","volume":"9","author":"PJ Easterbrook","year":"2024","unstructured":"Easterbrook PJ, Luhmann N, Bajis S, Min MS, Newman M, Lesi O, Doherty MC. WHO 2024 hepatitis B guidelines: an opportunity to transform care. Lancet Gastroenterol Hepatol. 2024;9:493\u20135.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"7455_CR6","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMra1610570","volume":"377","author":"EB Tapper","year":"2017","unstructured":"Tapper EB, Lok AS. Use of liver imaging and biopsy in clinical practice. N Engl J Med. 2017;377:756\u201368.","journal-title":"N Engl J Med"},{"key":"7455_CR7","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1016\/j.jhep.2020.06.025","volume":"73","author":"BA Davison","year":"2020","unstructured":"Davison BA, Harrison SA, Cotter G, Alkhouri N, Sanyal A, Edwards C, Colca JR, Iwashita J, Koch GG, Dittrich HC. Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials. J Hepatol. 2020;73:1322\u201332.","journal-title":"J Hepatol"},{"key":"7455_CR8","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.jhep.2015.04.006","volume":"63","author":"EASL-ALEH Clinical Practice Guidelines","year":"2015","unstructured":"EASL-ALEH Clinical Practice Guidelines. Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol. 2015;63:237\u201364.","journal-title":"J Hepatol"},{"key":"7455_CR9","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.jhep.2021.05.025","volume":"75","author":"EASL Clinical Practice","year":"2021","unstructured":"EASL Clinical Practice. Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis \u2013\u20092021 update. J Hepatol. 2021;75:659\u201389.","journal-title":"J Hepatol"},{"key":"7455_CR10","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1016\/j.jhep.2022.03.026","volume":"76","author":"QM Anstee","year":"2022","unstructured":"Anstee QM, Castera L, Loomba R. Impact of non-invasive biomarkers on hepatology practice: Past, present and future. J Hepatol. 2022;76:1362\u201378.","journal-title":"J Hepatol"},{"key":"7455_CR11","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/S2468-1253(24)00437-0","volume":"10","author":"A Liguori","year":"2025","unstructured":"Liguori A, Zoncap\u00e8 M, Casazza G, Easterbrook P, Tsochatzis EA. Staging liver fibrosis and cirrhosis using non-invasive tests in people with chronic hepatitis B to inform WHO 2024 guidelines: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2025;10:332\u201349.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"7455_CR12","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1053\/j.gastro.2019.08.060","volume":"158","author":"X Verhelst","year":"2020","unstructured":"Verhelst X, Dias AM, Colombel JF, Vermeire S, Van Vlierberghe H, Callewaert N, Pinho SS. Protein glycosylation as a diagnostic and prognostic marker of chronic inflammatory Gastrointestinal and liver diseases. Gastroenterology. 2020;158:95\u2013110.","journal-title":"Gastroenterology"},{"key":"7455_CR13","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.mam.2016.04.008","volume":"51","author":"M Takahashi","year":"2016","unstructured":"Takahashi M, Kizuka Y, Ohtsubo K, Gu J, Taniguchi N. Disease-associated glycans on cell surface proteins. Mol Aspects Med. 2016;51:56\u201370.","journal-title":"Mol Aspects Med"},{"key":"7455_CR14","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1002\/hep.21855","volume":"46","author":"XE Liu","year":"2007","unstructured":"Liu XE, Desmyter L, Gao CF, Laroy W, Dewaele S, Vanhooren V, Wang L, Zhuang H, Callewaert N, Libert C, et al. N-glycomic changes in hepatocellular carcinoma patients with liver cirrhosis induced by hepatitis B virus. Hepatology. 2007;46:1426\u201335.","journal-title":"Hepatology"},{"key":"7455_CR15","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1373\/clinchem.2009.139295","volume":"56","author":"EN Debruyne","year":"2010","unstructured":"Debruyne EN, Vanderschaeghe D, Van Vlierberghe H, Vanhecke A, Callewaert N, Delanghe JR. Diagnostic value of the hemopexin N-glycan profile in hepatocellular carcinoma patients. Clin Chem. 2010;56:823\u201331.","journal-title":"Clin Chem"},{"key":"7455_CR16","doi-asserted-by":"crossref","unstructured":"Su R, Tao X, Yan L, Liu Y, Chen CC, Li P, Li J, Miao J, Liu F, Kuai W et al. Early screening, diagnosis and recurrence monitoring of hepatocellular carcinoma in patients with chronic hepatitis B based on serum N-glycomics analysis: a cohort study. Hepatology 2025.","DOI":"10.1097\/HEP.0000000000001316"},{"key":"7455_CR17","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/nm1006","volume":"10","author":"N Callewaert","year":"2004","unstructured":"Callewaert N, Van Vlierberghe H, Van Hecke A, Laroy W, Delanghe J, Contreras R. Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics. Nat Med. 2004;10:429\u201334.","journal-title":"Nat Med"},{"key":"7455_CR18","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.1158\/1078-0432.CCR-16-1500","volume":"23","author":"X Verhelst","year":"2017","unstructured":"Verhelst X, Vanderschaeghe D, Cast\u00e9ra L, Raes T, Geerts A, Francoz C, Colman R, Durand F, Callewaert N, Van Vlierberghe H. A Glycomics-Based test predicts the development of hepatocellular carcinoma in cirrhosis. Clin Cancer Res. 2017;23:2750\u20138.","journal-title":"Clin Cancer Res"},{"key":"7455_CR19","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1007\/s00535-024-02206-8","volume":"60","author":"H Hanamatsu","year":"2025","unstructured":"Hanamatsu H, Suda G, Ohara M, Ogawa K, Tamaki N, Hikita H, Haga H, Maekawa S, Sugiyama M, Kakisaka T, et al. Elevated A2F bisect N-glycans of serum IgA reflect progression of liver fibrosis in patients with MASLD. J Gastroenterol. 2025;60:456\u201368.","journal-title":"J Gastroenterol"},{"key":"7455_CR20","doi-asserted-by":"publisher","first-page":"e29863","DOI":"10.1002\/jmv.29863","volume":"96","author":"R Su","year":"2024","unstructured":"Su R, Yan L, Jiang B, Li J, Li P, Liu Y, Miao J, Chen C, Xu L, Ren L, Mi Y. A novel model based on serum N-glycan markers for evaluating stage of liver necroinflammation in treatment-na\u00efve chronic hepatitis B patients. J Med Virol. 2024;96:e29863.","journal-title":"J Med Virol"},{"key":"7455_CR21","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1186\/s12964-024-01569-y","volume":"22","author":"Z Li","year":"2024","unstructured":"Li Z, Zhang N, Dong Z, Wang X, Zhou J, Gao J, Yang Y, Li J, Guan F, Zhou Y, Tan Z. Integrating transcriptomics, glycomics and glycoproteomics to characterize hepatitis B virus-associated hepatocellular carcinoma. Cell Commun Signal. 2024;22:200.","journal-title":"Cell Commun Signal"},{"key":"7455_CR22","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s10719-021-09975-x","volume":"38","author":"M Kuang","year":"2021","unstructured":"Kuang M, Wu H, Hu L, Guo X, He D, Liu B, Chen M, Gu J, Gu J, Zeng X, Ruan Y. Up-regulation of FUT8 inhibits TGF-\u03b21-induced activation of hepatic stellate cells during liver fibrogenesis. Glycoconj J. 2021;38:77\u201387.","journal-title":"Glycoconj J"},{"key":"7455_CR23","doi-asserted-by":"publisher","first-page":"4109","DOI":"10.7150\/jca.58268","volume":"12","author":"C Liao","year":"2021","unstructured":"Liao C, An J, Yi S, Tan Z, Wang H, Li H, Guan X, Liu J, Wang Q. FUT8 and protein core fucosylation in tumours: from diagnosis to treatment. J Cancer. 2021;12:4109\u201320.","journal-title":"J Cancer"},{"key":"7455_CR24","doi-asserted-by":"publisher","first-page":"893365","DOI":"10.3389\/fimmu.2022.893365","volume":"13","author":"B Radovani","year":"2022","unstructured":"Radovani B, Gudelj I. N-Glycosylation and Inflammation; the Not-So-Sweet relation. Front Immunol. 2022;13:893365.","journal-title":"Front Immunol"},{"key":"7455_CR25","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1186\/1476-4598-9-215","volume":"9","author":"M Fang","year":"2010","unstructured":"Fang M, Dewaele S, Zhao YP, St\u00e4rkel P, Vanhooren V, Chen YM, Ji X, Luo M, Sun BM, Horsmans Y, et al. Serum N-glycome biomarker for monitoring development of DENA-induced hepatocellular carcinoma in rat. Mol Cancer. 2010;9:215.","journal-title":"Mol Cancer"},{"key":"7455_CR26","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1021\/pr050328x","volume":"5","author":"MA Comunale","year":"2006","unstructured":"Comunale MA, Lowman M, Long RE, Krakover J, Philip R, Seeholzer S, Evans AA, Hann HW, Block TM, Mehta AS. Proteomic analysis of serum associated fucosylated glycoproteins in the development of primary hepatocellular carcinoma. J Proteome Res. 2006;5:308\u201315.","journal-title":"J Proteome Res"},{"key":"7455_CR27","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1093\/glycob\/cwp134","volume":"19","author":"O Gornik","year":"2009","unstructured":"Gornik O, Wagner J, Puci\u0107 M, Knezevi\u0107 A, Redzic I, Lauc G. Stability of N-glycan profiles in human plasma. Glycobiology. 2009;19:1547\u201353.","journal-title":"Glycobiology"},{"key":"7455_CR28","doi-asserted-by":"publisher","unstructured":"Higashi M, Yoshimura T, Usui N, Kano Y, Deguchi A, Tanabe K, Uchimura Y, Kuriyama S, Suzuki Y, Masaki T, Ikenaka K. A potential serum N-glycan biomarker for hepatitis C virus-related early-stage hepatocellular carcinoma with liver cirrhosis. Int J Mol Sci. 2020;21(23):8913. https:\/\/doi.org\/10.3390\/ijms21238913","DOI":"10.3390\/ijms21238913"},{"key":"7455_CR29","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/s41575-022-00649-z","volume":"19","author":"A Kramvis","year":"2022","unstructured":"Kramvis A, Chang KM, Dandri M, Farci P, Glebe D, Hu J, Janssen HLA, Lau DTY, Penicaud C, Pollicino T, et al. A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook. Nat Rev Gastroenterol Hepatol. 2022;19:727\u201345.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"7455_CR30","doi-asserted-by":"publisher","first-page":"S60","DOI":"10.1016\/j.jhep.2016.01.028","volume":"64","author":"MK Maini","year":"2016","unstructured":"Maini MK, Gehring AJ. The role of innate immunity in the immunopathology and treatment of HBV infection. J Hepatol. 2016;64:S60\u201370.","journal-title":"J Hepatol"},{"key":"7455_CR31","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/S0140-6736(09)60207-5","volume":"373","author":"YF Liaw","year":"2009","unstructured":"Liaw YF, Chu CM. Hepatitis B virus infection. Lancet. 2009;373:582\u201392.","journal-title":"Lancet"},{"key":"7455_CR32","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1002\/hep.31506","volume":"73","author":"DTY Lau","year":"2021","unstructured":"Lau DTY, Ganova-Raeva L, Wang J, Mogul D, Chung RT, Lisker-Melman M, Chang KM, Shaikh OS, Janssen HLA, Wahed AS, Lok AS. Precore and basal core promoter hepatitis B virus (HBV) variants are present from a young age and differ across HBV genotypes. Hepatology. 2021;73:1637\u201351.","journal-title":"Hepatology"},{"key":"7455_CR33","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.jhep.2010.02.035","volume":"53","author":"GV Papatheodoridis","year":"2010","unstructured":"Papatheodoridis GV, Lampertico P, Manolakopoulos S, Lok A. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. J Hepatol. 2010;53:348\u201356.","journal-title":"J Hepatol"},{"key":"7455_CR34","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1074\/mcp.M800470-MCP200","volume":"8","author":"D Vanderschaeghe","year":"2009","unstructured":"Vanderschaeghe D, Laroy W, Sablon E, Halfon P, Van Hecke A, Delanghe J, Callewaert N. GlycoFibroTest is a highly performant liver fibrosis biomarker derived from DNA sequencer-based serum protein glycomics. Mol Cell Proteom. 2009;8:986\u201394.","journal-title":"Mol Cell Proteom"},{"key":"7455_CR35","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73\u201384.","journal-title":"Hepatology"},{"key":"7455_CR36","doi-asserted-by":"publisher","first-page":"S138","DOI":"10.1002\/hep.22883","volume":"49","author":"CL Thio","year":"2009","unstructured":"Thio CL. Hepatitis B and human immunodeficiency virus coinfection. Hepatology. 2009;49:S138\u2013145.","journal-title":"Hepatology"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-025-07455-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-07455-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-07455-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T12:47:44Z","timestamp":1770986864000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-025-07455-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,25]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["7455"],"URL":"https:\/\/doi.org\/10.1186\/s12967-025-07455-6","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,25]]},"assertion":[{"value":"3 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Biomedical Ethics Committee of Peking University (approval number: IRB00001052-23167) and conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors declare no conflicts of interest that pertain to this work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"244"}}